Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes

Toxicology and Applied Pharmacology

Volumn 272, Issue 1, 2013, Pages 245-255

  Doherty, Kimberly R ^a   Wappel, Robert L ^a   Talbert, Dominique R ^a   Trusk, Patricia B ^a   Moran, Diarmuid M ^a   Kramer, James W ^b   Brown, Arthur M ^b   Shell, Scott A ^a   Bacus, Sarah ^a  

^a IQVIA   (United States)

^b ChanTest Corporation   (United States)

Author keywords

Cardiomyocytes; Cardiotoxicity; Drug evaluation; In vitro; Preclinical; Tyrosine kinase inhibitors

Indexed keywords

CALCIUM CHANNEL CAV1.2; CASPASE 3; CASPASE 7; CHOLESTEROL; CRIZOTINIB; ERLOTINIB; ION CHANNEL; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; POTASSIUM CHANNEL HERG; REACTIVE OXYGEN METABOLITE; SODIUM CHANNEL NAV1.5; SUNITINIB; SUPEROXIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL DEATH; CELL STRUCTURE; CELL VIABILITY; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG SAFETY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIPID STORAGE; SIGNAL TRANSDUCTION;

CARDIOMYOCYTES; CARDIOTOXICITY; DRUG EVALUATION; IN VITRO; PRECLINICAL; TYROSINE KINASE INHIBITORS;

CASPASE 3; CASPASE 7; CELL SURVIVAL; CELLS, CULTURED; CHOLESTEROL; ENZYME ACTIVATION; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INDOLES; ION CHANNELS; LIPIDS; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PLURIPOTENT STEM CELLS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIDINES; PYRIMIDINES; PYRROLES; QUINAZOLINES; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA;

ANIMALIA;

EID: 84884134230     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.04.027     Document Type: Article

References (49)

1. Cai L., Wang Y., Zhou G., Chen T., Song Y., Li X., Kang Y.J. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 2006, 48(8):1688-1697.
2. Chen M.H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118(1):84-95.
3. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., Woulfe K., Pravada E., Cassiola F., Desai J. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
4. ClinicalTrials.gov Health effects after anthracycline and radiation therapy (HEART): dexrazoxane and prevention of anthracycline-related cardiotoxicity (Verified 2013 Feb. Accessed 2013 March). http://clinicaltrials.gov/ct2/show/NCT01790152?term=anthracycline+and+HEART+and+cardiomyopathy&rank=1.
5. ClinicalTrials.gov Rosuvastatin in treating women with cardiovascular complication (Accessed 2013 March 14). http://clinicaltrials.gov/ct2/show/NCT01051401?term=rosuvastatin+and+women&rank=5.
6. ClinicalTrials.gov Study of CoQ10 during one cycle of doxorubicin treatment for breast cancer (Verified 2013 Feb. Accessed 2013 March 14). http://clinicaltrials.gov/ct2/show/NCT00976131?term=CoQ10+and+Doxorubicin&rank=1.
7. Cohen J.D., Babiarz J.E., Abrams R.M., Guo L., Kameoka S., Chiao E., Taunton J., Kolaja K.L. Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol. Appl. Pharmacol. 2011, 257:74-83.
8. DeAtley S., Aksenov M., Akenova M., Harris B., Hadley R., Cole Harper P., Carney JB D.A. Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. Cancer Lett. 1999, 136(1):41-46.
9. Deb A., Wang S., Skelding K.A., Miller D., Simper D., Caplice N.M. Bone marrow-derived cardiomyocytes are present in adult human heart: a study of gender-mismatched bone marrow transplantation patients. Circulation 2003, 107(9):1247-1249.
10. Demetri G.D., Casali P.G., Blay J.Y., von Mehren M., Morgan J.A., Bertulli R., Ray-Coquard I., Cassier P., Davey M., Borghaei H. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin. Cancer Res. 2009, 15(18):5910-5916.
11. Dykens J.A., Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 2007, 12(17-18):777-785.
12. Eschenhagen T., Force T., Ewer M.S., de Keulenaer G.W., Suter T.M., Anker S.D., Avkiran M., de Azambuja E., Balligand J.-L., Brutsaert D.L. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2011, 13:1-10.
13. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 2006, 24(1):25-35.
14. Force T., Kolaja K.L. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 2011, 10:111-126.
15. Freebern W.J., Fang Hengsheng S., Slade Martin D., Wells Susan, Canale Jennifer, Megill John, Grubor Branka, Shi Hong, Fletcher Anthony, Lombardo Louis, Levesque Paul, Lee Francis Y., Sasseville Vito G. In vitro cardiotoxicity potential comparative assessments of chronic myelogenous leukemia tyrosine kinase inhibitor therapies: dasatinib, imatinib and nilotinib. Blood 2007, 110.
16. Gianni L., Herman E.H., Lipshultz S.E., Minotti G., Sarvazyan N., Sawyer D.B. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 2008, 26(22):3777-3784.
17. Gordon A.N., Finkler N., Edwards R.P., Garcia A.A., Crozier M., Irwin D.H., Barrett E. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int. J. Gynecol. Cancer 2005, 15(5):785-792.
18. Guo L., Abrams R.M., Babiarz J.E., Cohen J.D., Kameoka S., Sanders M.J., Chiao E., Kolaja K.L. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 2011, 123(1):281-289.
19. ICH S7A, safety pharmacology studies for human pharmaceuticals (Accessed February 15, 2012). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf.
20. ICH S7B, the nonclinical evaluation of the potential for delayed ventricular repolarization (QT prolongation) by human pharmaceuticals (Accessed February 15, 2012). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf.
21. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26(1):127-132.
22. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F.J., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006, 12(8):908-916.
23. Kerkela R., Woulfe K.C., Durand J.-B., Vagnozzi R., Kramer D., Chu T.F., Beahm C., Chen M.-H., Force T. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2009, 2(1):15-25.
24. Khosravan R., Toh M., LaFargue J., Ni G., Bello C. Sunitinib pharmokinetic (PK) and safety data in subejcts with renal impairment and hemodialysis 2008.
25. Kim T.D., le Coutre P., Schwarz M., Grille P., Levitin M., Fateh-Moghadam S., Giles F.J., Dorken B., Haverkamp W., Kohncke C. Clinical cardiac safety profile of nilotinib. Hematologica 2012, 97(6):883-889.
26. Loor G., Kondapalli J., Iwase H., Chandel N.W., GB Guzy R., Vanden Hoek T., Schumacker P. Mitochondrial oxidant stress triggers cell death in simulated ischemia-reperfusion. Biochim. Biophys. Acta 2011, 1813(7):1382-1394.
27. Mellor H.R., Bell A.R., Valentin J.P., Roberts R.R. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 2011, 120(1):14-32.
28. Ou S.-H., Azada M., Dy J., Stiber J.A. Asymptomatic profound sinus bradycardia (heart rate≤45) in non-small cell lung cancer patients treated with crizotinib. J. Thorac. Oncol. 2011, 6(12).
29. Pfizer I Clinical Pharmacology Review (Accessed November 27, 2012). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf.
30. Pfizer I Pharmacology/toxicology NDA/BLA review and evaluation (Accessed April 10, 2012). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000PharmR.pdf.
31. Reck M., van Zandwijk N., Gridelli C., Baliko Z., Rischin D., Allan S., Krzakowski M., Heigener D. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J. Thorac. Oncol. 2010, 5(10):1616-1622.
32. Reck M., Mok T., Wolf J., Heigener D., Wu Y.L. Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opin. Drug Saf. 2011, 10(1):147-157.
33. Schaefer G., Shao L., Totpal K., Akita R.W. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res. 2007, 67(3):1228-1238.
34. Schmidinger M., Zielinski C.C., Vogl U.M., Bojic A., Bojic M., Schukro C., Ruhsam M., Hejna M., Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26(32):5204-5212.
35. Shanks N., Greek R., Greek J. Are animal models predictive for humans?. Philos. Ethics Humanit. Med. 2009, 4:2.
36. Spector N.L., Yarden Y., Smith B., Lyass L., Trusk P., Pry K., Hill J.E., Xia W., Seger R., Bacus S.S. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(25):10607-10612.
37. Sun X., Pan H., Tan HY Y. High free fatty acids level related with cardiac dysfunction in obese rats. Diabetes Res. Clin. Pract. 2012, 95(2):251-259.
38. Sutent [package insert]. New York, NY: Pfizer Labs; 2006.
39. Tarceva [package insert]. Melville, NY: OSI Pharmaceuticals Inc.; 2010.
40. Tasigna [package insert]. East Hanover, N.J.: Novartis Pharmaceuticals Corp.; 2010.
41. Turner J.R. Translational cardiovascular safety: a primer of non-clinical investigations for clinical scientists. J. Clin. Stud. 2011, 4(1):50-61.
42. Turner R., Durham T. Integrated Cardiac Safety 2009, John Wiley and Sons, (396 pp.).
43. Vanden Hoek T.L., Qin Y., Wojcik K.R., Li C.Q., Shao Z.H., Anderson T., Becker L.B., Hamann K.J. Reperfusion, not simulated ischemia, initiates intrinsic apoptosis injury in chick cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2003, 284(1):H141-H150.
44. Wible B.A., Kuryshev Y.A., Smith S.S., Liu Z., Brown A.M. An ion channel library for drug discovery and safety screening on automated platforms. Assay Drug Dev. Technol. 2008, 6(6):765-780.
45. Will Y., Dykens J.A., Nadanaciva S., Hirakawa B., Jamieson J., Marroquin L.D., Hynes J., Patyna S., Jessen B.A. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 2008, 106(1):153-161.
46. Wolf A., Couttet P., Dong M., Grenet O., Heron M., Junker U., Ledieu D., Mahl A., Marrer E., Persohn E. Preclinical evaluation of potential nilotinib cardiotoxicity. Leuk. Res. 2011, 35:631-637.
47. Xalkori [package insert]. New York, NY: Pfizer Labs; 2011.
48. Xu Z., Cang S., Yang T., Liu D. Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia. Hematol. Rev. 2009, 1:17-21.
49. Zhao Y., Xue T., Yang X., Zhu H., Ding X., Lou L., Lu W., Yang B., He Q. Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicol. Appl. Pharmacol. 2010, 248(1):20-27.